Key result
In patients undergoing TAVR for severe aortic stenosis, co-existing hypertrophic cardiomyopathy was associated with significantly higher mortality (OR 5.79; 95% CI 3.38-9.91; p<0.0001).
Why the study?
The outcomes of transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis co-existing with hypertrophic cardiomyopathy (HCM) are unclear.
Does co-existing hypertrophic cardiomyopathy increase mortality and complications in patients undergoing TAVR for severe aortic stenosis?
Meta-Analysis
Does co-existing hypertrophic cardiomyopathy increase mortality and complications in patients undergoing TAVR for severe aortic stenosis?
In patients with severe aortic stenosis, the presence of co-existing hypertrophic cardiomyopathy is associated with significantly worse outcomes following TAVR, including a nearly six-fold increase in mortality.
BACKGROUND: The co-existence of severe aortic stenosis (AS) and hypertrophic cardiomyopathy (HCM) is not uncommon. Surgical intervention is the gold standard management. Patients with high surgical risk might undergo transcatheter aortic valve replacement (TAVR). However, TAVR outcomes are unclear in this population. We aimed to investigate the impact of HCM on the outcomes of TAVR. AIM: We aim to investigate the outcomes of TAVR in patients with HCM. METHODS: We systematically searched PubMed, EMBASE, and Scopus for studies that compared outcomes of TAVR procedure between patients with HCM and those without it. Using the random-effects model, the odds ratios (OR) with 95% confidence interval (CI) were reported. RESULTS: We screened 102 articles and identified three observational cohort studies. Compared to patients who underwent TAVR without underlying HCM, TAVR for AS co-existed with HCM was associated with higher rates of mortality (OR 5.79; 95% CI: 3.38; 9.91, p < 0.0001), cardiogenic shock (OR 4.55; 95% CI: 3.40; 6.08, p < 0.0001), aortic dissection (OR 4.95; 95% CI: 3.17; 7.74, p < 0.0001), vascular complications (OR 2.10; 95% CI: 1.27; 3.47, p = 0.004), and renal impairment (OR 1.80; 95% CI: 1.36; 2.40, p < 0.0001). There was no difference between the comparison groups in terms of complete heart block, new permanent pacemaker implantation, or bleeding. CONCLUSION: In patients with severe AS and HCM, TAVR was associated with significantly higher occurrence of mortality, cardiogenic shock, aortic dissection, vascular complications, and renal impairment as well as the need for mechanical ventilation than patients who did not have HCM.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2025) conducted a meta-analysis in Severe aortic stenosis and hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy (HCM) vs. No underlying HCM was evaluated on Mortality (OR 5.79, 95% CI 3.38-9.91, p=<0.0001). In patients undergoing TAVR for severe aortic stenosis, co-existing hypertrophic cardiomyopathy was associated with significantly higher mortality (OR 5.79; 95% CI 3.38-9.91; p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: